FLT3

ASH 2018 | Phase II RADIUS study of standard of care with or without midostaurin after allogeneic SCT in patients with FLT3-ITD…

Cynthia Umukoro , Jan 4, 2019 , Expert Opinion

IDH1/2

ASH 2018 | Ivosidenib or enasidenib in combination with induction and consolidation therapy in newly diagnosed acute myeloid…

Cynthia Umukoro , Jan 4, 2019

FLT3

ASH 2018 | Final safety and efficacy data from the phase III QuANTUM-R study

Cynthia Umukoro , Dec 21, 2018 , Expert Opinion

General AML

Sabine Kayser | ASH 2018 | Outcomes of older patients with APL treated with or without ATO

Cynthia Umukoro , Dec 20, 2018

FLT3

ASH 2018 | Maintenance therapy with sorafenib in patients with FLT3-ITD acute myeloid leukemia – SORMAIN trial

Cynthia Umukoro , Dec 20, 2018 , Expert Opinion

General AML

Daniel Pollyea | ASH 2018 | Venetoclax in combination with HMAs in patients with AML ineligible for intensive therapy

Cynthia Umukoro , Dec 19, 2018

General AML

ASH 2018 | Genetic characterization of older acute myeloid leukemia patients treated in the phase III NILG 02/06 trial

Cynthia Umukoro , Dec 19, 2018

IDH1/2

ASH 2018 | Ivosidenib (AG-120) in patients with  previously untreated IDH1-mutant acute myeloid leukemia

Philippa Redondo , Dec 19, 2018 , Expert Opinion

General AML

David Sallman | ASH 2018 | Key results of the phase I THINK trial of NKG2D CAR-T therapy in R/R AML

Cynthia Umukoro , Dec 18, 2018

General AML

Joshua Zeidner | ASH 2018 | Biomarker-guided phase II study in MCL-1 dependent R/R AML patients

Cynthia Umukoro Stephanie Hill , Dec 18, 2018